|Calithera Biosciences Inc. (NASDAQ:CALA) Tumbles 10% On preclinical data of CB-839|
|By William Kent|
|Tuesday, 21 April 2015 14:24|
Clinical-stage pharmaceutical firm, Calithera Biosciences Inc. (NASDAQ:CALA), has confirmed the preclinical data for the main anti-cancer therapeutic candidate, CB-839.
The company, which is focused on discovering novel small molecule drugs treating cancer, has Calithera's novel, orally bioavailable glutaminase inhibitor, at American Association for Cancer Research that is happening from April 18 to 22nd this year in Philadelphia, Pennsylvania.
CB-839 is a powerful and orally bioavailable glutaminase inhibitor which is currently in clinical trains especially in phase I.
Susan Molineaux, PhD, President and Chief Executive Officer of Calithera, opined that the firm has identified KRAS and EGFR mutation status as potential biomarkers which may direct the development of CB-839 in non-small cell lung cancer.
Besides this, CB-839 along with signal transduction inhibition can provide novel therapeutic strategy for treating non-small cell lung cancer as well as renal cell carcinoma.
This data would be provided by Lindsey Boroughs from laboratory of Ralph Debaradinis at University of Texas Southwestern which has been given title of "Evaluation of the glutaminase inhibitor CB-839 in non-small cell lung cancer,".
The data would be showing that lung cancer cell lines having EGFR or KRAS mutations have more sensitivity to CB-839. The data would also be given by Frank Parlati, Senior Director of Biology, in another session "CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity".
CB-839 was also the topic of a poster given by the company’s collaborator Arimichi Okazaki from Laboratory of Othon Iliopoulos at Massachusetts General Hospital titled, "Glutaminase inhibitors suppress pyrimidine synthesis and promote DNA replication stress in Von Hippel-Lindau (VHL) deficient human renal cells."
This data shows that CB-839 puts in double stranded breaks in VHL deficient renal cell carcinoma cells as well as PARP inhibitors.
Shares of the company fell 10% to $14.45.